

in some cases.

Use this code with your phone's QR code reader to

This ¹/4-Folded Guide is a companion to the New York State Department of Health AIDS Institute guideline HIV Testing. Full guideline is available at hivguidelines.org.

go directly to a mobile-friendly version of this guideline.

· If HIV-1 RNA is not detected and the Geenius Reader interpretation is

- HIV-2 indeterminate or HIV indeterminate, an HIV-2 NAT may be warranted.
- HIV-1 RNA Nucleic Acid Testing (Step 3)

- · If the person being tested is taking antiretroviral agents as PEP, PrEP, or for
- rapid ART initiation, a false negative result for the HIV-1 RNA test may occur.
- Step 1: HIV-1/2 Antigen/Antibody Immunoassay For initial HIV testing (aka "screening"), clinicians should use an HIV-1/2 Ag/Ab immunoassay (formerly known as the "4th-generation" test). (A2) · For initial testing of newborns or individuals who are in labor, being evaluated

HIV tests that are not recommended

Laboratory HIV screening tests

(rA) .r-VIH dtiw stneiteq to

(SA) .eleubivibni

panuiiuon

Diagnosis of HIV-2 Intection

HIV Transmission in the United States.

point-of-care HIV screening tests

Rapid HIV screening tests

· Home-based tests

Alternative HIV tests (oral and urine specimens)

ΣΥΝ ΝΙ ΞΙΒΑΙΙΑΥΑ ΣΥΑΣΣΑΟΝUMMI VIH

(rA) .TAN ANA r-VIH mortor bluods ansicians (r-VIH

· Clinical Laboratory Improvement Amendments (CLIA)-waived

screening and diagnostic tests available for use in NYS, including: VIH bevorage ADT no notsemotion for information on FDA-approved HV

evaluation for HV-2 infection that is similar in scope to the evaluation

· When HIV-2 antibodies are detected, clinicians should perform a clinical

Pregnant Women with HIV Infection and Interventions to Reduce Perinatal

by HIV-1 NAT; initiation of ART is strongly recommended for pregnant

ART when pregnant individuals are diagnosed with acute HIV infection · Clinicians should not wait for serologic confirmation of HIV to initiate

Step 3: HIV-1 Nucleic Acid Testing (qualitative or quantitative HIV RNA testing)

· To determine the HIV status of an infant born to an individual with

- See DHHS: Recommendations for the Use of Antiretroviral Drugs in

- · If the Geenius HIV 1/2 Supplemental Assay interpretation is nonreactive or indeterminate for any HIV type (HIV-1, HIV-2, or untypable HIV), test the specimens for HIV-1 RNA, even if the result is HIV-2 indeterminate.

· Nonspecific reactivity could cause an HIV-2 indeterminate result to occur

HIV-1/HIV-2 Antibody Differentiation Immunoassay (Step 2)

- HIV testing services at the Wadsworth Center, which is free of charge for NYS clinicians providing care for HIV-exposed infants. For information about this service, contact the Wadsworth Center at 518-486-9605.
- laboratory to ensure the specimen will be suitable for all tests in the algorithm. · NYSDOH strongly recommends that all NYS birth facilities use the pediatric
- · Consult the specimen collection and handling instructions provided by the
- When possible, collect blood by venipuncture for laboratory submission.
- · Become familiar with the laboratory's internal testing algorithm and results-reporting policies. Many labs will reflex additional screening steps (such as HIV Ab differentiation immunoassay and HIV RNA) on the original sample without supplemental orders. Other labs may require additional samples or supplemental orders to complete all steps in the algorithm.

HIV-1/2 Antigen/Antibody Immunoassay (Step 1)

8- KEY POINTS

P.3

ALL RECOMMENDATIONS (continued from P.2) 2.q

(r.9 morit beunitions) **SNOITAGNAEMODAS 11A**

MAY 2022

P.1

beunitno) ypszponummi yboditnA/nepitnA s/r-VIH :r qet2

or refer the patient for prevention services. (A3) with any patient who reports recent or likely ongoing HIV risk exposures oriented, harm-reduction strategies, including PrEP and emergency PEP, In the case of a nonreactive result, the clinician should discuss goal-

HIV CLINICAL RESOURCE 📕 1/4-FOLDED GUIDE

/ISIT HIVGUIDELINES.ORG TO LEARN MORE OR VIEW COMPLETE GUIDE

· Clinicians must perform diagnostic HIV laboratory tests in full compliance

· Clinicians must report confirmed cases of HIV according to NYS law

available from the NYSDOH Wadsworth Center (518-474-2163).

See full guideline for overview of NYS public health law HIV testing

for PEP, or unlikely to return for test results, clinicians should use an FDA-approved HIV screening test that provides results within 60 minutes

· Because all initial HIV tests are subject to false positive results, clinicians

should consider all reactive initial test results preliminary and perform appropriate laboratory diagnostic testing to confirm a patient's HIV status. (A1)

· Clinicians should educate patients about the limitations of in-home

and reactive results of any in-home HIV testing. (A3)

testing and emphasize that a laboratory should repeat both nonreactive

(A2); otherwise, rapid tests are not recommended for step 1 of the standard

· Additional information regarding testing procedures and regulations is

(see NYSDOH Provider Reporting and Partner Services).

HIV Testing With the Standard 3-Step Algorithm

HIV TESTING

with NYS HIV/AIDS Laws and Regulations.

NYSDOH AIDS INSTITUTE HIV CLINICAL GUIDELINE

(£A) .97usoqx9 VIH acute HIV is suspected, for as long as an individual remains at high risk of • Clinicians should offer repeat HIV testing every 3 months, or sooner if

Step 2: HIV-2 Antibody Differentiation Immunoassay

- (IA) .(A) Alferentiation immunoassay. should perform supplemental testing (step 2) with an FDA-approved obtained with an HIV-1/2 Ag/Ab immunoassay testing (step 1), clinicians Per the standard HIV laboratory testing algorithm, if a reactive result is
- Refer to the NYSDOH AI guideline When to Initiate ART, With Protocol for rapid ART initiation and transmission prevention counseling. (A1) for HIV-1 or HIV-2 Abs, the clinician should provide or refer the patient ۰ اf the result of the VIH of the residual (۲۹۹ کا the result of the result of the result of the residual of
- undifferentiated (i.e., reactive for both HIV-1 and HIV-2), repeat - Note: If the HIV Ab differentiation assay result is positive but for Rapid Initiation.
- testing may determine if the patient has HIV-1 or HIV-2 infection.
- Step 3: HIV-1 Nucleic Acid Testing (qualitative or quantitative HIV RNA testing)
- of HIV-1 RNA and confirm or exclude HIV-1 infection. (A*) should immediately order HIV-1 RUA VAN (step 3) to detect the presence HIV-1 or HIV-2), and the lab does not perform reflex testing, the clinician nonreactive (negative), indeterminate (neither positive nor negative for If the HIV-1/2 Ab differentiation immunoassay (step 2) result is
- (IA) .noissiment VIH travent of gnilesnuos the acute HIV-1 diagnosis, recommend ART initiation, and prioritize If HIV-1 RNA is detected, the clinician should inform the patient of


NEW YORK STATE LAW

requirements (Box 1).

ALL RECOMMENDATIONS

HIV laboratory testing algorithm.

FIGURE 2: HIV Laboratory Testing Algorithm [a]



Abbreviations: Ab, antibody; Ag, antigen; APHL, Association of Public Health Laboratories; CDC, Centers for Disease Control and Prevention; ind, indeterminate; FDA, U.S. Food and Drug Administration; NAT, nucleic acid test; NYSDOH, New York State Department of Health; PEP, post-exposure prophylaxis; PrEP, pre-exposure prophylaxis.

Notes:

- a. Adapted from CDC 2018 Quick reference guide: Recommended laboratory HIV testing algorithm for serum or plasma specimens and APHL Suggested reporting language for the HIV laboratory diagnostic testing algorithm.
- b. APHL and CDC continue to recommend that laboratories use an FDA-approved instrumented HIV-1/HIV-2 Ag/Ab immunoassay as the initial assay in the laboratory HIV testing algorithm for serum or plasma due to their superior sensitivity for detecting acute HIV infection. However, the FDA-approved single-use rapid HIV-1/ HIV-2 Ag/Ab immunoassay may be used as the initial assay in the laboratory HIV testing algorithm for serum or plasma if an instrumented assay is not available.
- c. Become familiar with the laboratory's internal testing algorithm and results-reporting policies. Many labs will reflex additional screening steps (such as HIV Ab differentiation immunoassay and HIV RNA) on the original sample without supplemental orders. Other labs may require additional samples or supplemental orders to complete all steps in the algorithm.
- d. This includes specimens reported as HIV-2 positive with HIV-1 cross-reactivity.
- e. Further testing may be performed to determine type.
- f. Per the Geenius package insert, specimens with this final assay interpretation should be retested with a new cartridge. If the final assay interpretation is again HIV-2 indeterminate, it should be reported as such and followed with an HIV-1 NAT.
- g. Most laboratories reflex directly to an HIV-1 RNA test without requiring an additional test order or new specimen, either by performing the test in-house or referring the specimen to another laboratory. If the laboratory is unable to or does not automatically reflex directly to the RNA test, clinicians should order an HIV-1 RNA test as soon as possible. To reflex directly to an HIV-1 RNA test, a test kit approved by either the FDA or NYSDOH to aid in diagnosing HIV-1 infection is required. If HIV-1 RNA is detected, acute HIV-1 is present, and clinicians should proceed with clinical evaluation. If no HIV-1 RNA is detected, the initial immunoassay result is presumed false positive.
- h. A negative HIV-1 NAT result and repeatedly HIV-2 indeterminate or HIV indeterminate antibody differentiation immunoassay result should be referred for testing with a different validated supplemental HIV-2 test (antibody test or NAT) if available. Alternatively, redraw and repeat algorithm in 2 to 4 weeks to assess HIV-2 infection.